Sensorion Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Sensorion heeft een totaal eigen vermogen van €83.5M en een totale schuld van €1.6M, wat de schuld-eigenvermogensverhouding op 2% brengt. De totale activa en totale passiva bedragen respectievelijk €101.5M en €18.1M.

Belangrijke informatie

2.0%

Verhouding schuld/eigen vermogen

€1.65m

Schuld

Rente dekkingsratio	n/a
Contant	€87.34m
Aandelen	€83.46m
Totaal verplichtingen	€18.07m
Totaal activa	€101.53m

Recente financiële gezondheidsupdates

Geen updates

Recent updates

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( €98.0M ) RFM } overtreffen de korte termijn passiva ( €14.2M ).

Langlopende schulden: De kortetermijnactiva RFM ( €98.0M ) overtreffen de langetermijnschulden ( €3.9M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: RFM heeft meer geld in kas dan de totale schuld.

Schuld verminderen: De schuld/eigen vermogen-ratio van RFM is de afgelopen 5 jaar gedaald van 922.3% naar 2%.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: RFM heeft op basis van de huidige vrije kasstroom voldoende cash runway voor meer dan 3 jaar.

Voorspelling contante baan: RFM heeft voldoende kasruimte voor 1.8 jaar als de vrije kasstroom blijft dalen met een historisch percentage van 16.7 % per jaar.

Sensorion Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Recent updates

First half 2024 earnings released

Sensorion Announces Positive Recommendation From the Data Safety Monitoring Board (DSMB) Regarding the Continuation of NOTOXIS, its Phase 2a Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity

Sensorion Announces New Positive Secondary Efficacy Endpoints Data from Sens-401 Phase 2A Clinical Trial for the Preservation of Residual Hearing Loss

Sensorion Announces Appointment of Laurene Danon as Chief Financial Officer

New major risk - Revenue and earnings growth

Sensorion SA, Annual General Meeting, May 29, 2024

Sensorion SA has completed a Follow-on Equity Offering in the amount of €15.482057 million.

Sensorion Meets Primary Endpoint for Sens-401 Phase 2A Clinical Study for Residual Hearing Preservation

Sensorion SA to Report Fiscal Year 2023 Results on Mar 14, 2024

Sensorion Announces the Completion of Patient Inclusion in Phase 2A Clinical Trial of Sens-401 for Residual Hearing Preservation After Cochlear Implantation

Sensorion Appoints Federico Mingozzi as Non-Executive Director to the Board of Directors

Sensorion Announces Approval to Initiate Lead Gene Therapy Candidate Sens-501 into a Phase 1/2 Clinical Trial in Some European Countries

Sensorion SA Appoints Bernd Schmidt as New Chief Technical Officer

Sensorion SA, Annual General Meeting, Dec 20, 2023

New minor risk - Market cap size

Sensorion SA announced that it has received €33.214286 million in funding from Sofimac Innovation SAS, The Invus Group, LLC, Redmile Group, LLC

Sensorion SA announced that it has received €33.214286 million in funding from Sofimac Innovation SAS, The Invus Group, LLC, Redmile Group, LLC

Sensorion SA to Report Q2, 2023 Results on Sep 18, 2023

New major risk - Revenue and earnings growth

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

Sensorion Submits Clinical Trial Application for OTOF-GT, its Lead Gene Therapy Candidate, in Europe

Sensorion Sa Submits Clinical Trial Application for Lead Gene Therapy Candidate Otof-Gt in the Uk

Sensorion Reports Positive Efficacy Data from SENS-401 Phase 2a Clinical Study

Sensorion SA Announces First Patient Enrolled in Phase 2a Proof of Concept Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity

Less than half of directors are independent

Sensorion Announces US FDA Grants Rare Pediatric Disease Designation to Otof-Gt for the Treatment of Otoferlin Gene-Mediated Hearing Loss

Sensorion SA Announces Approval to Initiate amended Phase 2a Proof of Concept Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity in France

Sensorion Announces First Patient Enrolled in Proof-of-Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation

Sensorion SA to Report First Half, 2022 Results on Sep 22, 2022

Sensorion Announces Approval in Australia to Initiate Proof of Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation

Sensorion Announces Approval in France to Initiate Proof of Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation

Sensorion SA, Annual General Meeting, May 31, 2022

Less than half of directors are independent

Sensorion SA to Report Fiscal Year 2021 Results on Oct 31, 2022

Sensorion SA Updates on SENS-401 Phase 2 Trial in Sudden Sensorineural Hearing Loss

First half 2021 earnings released

Sensorion Announces Regulators Approval for Sensorion’s Amendment to Phase 2 Audible-S Trial of SENS-401 in Sudden Sensorineural Hearing Loss

Sensorion and Cochlear to Begin First Clinical Trial of SENS-401 for Hearing Preservation in Combination with Cochlear Implantation

Sensorion Presents New Preclinical Data on SENS-401 at ARO 2021

Sensorion Announces Third Gene Therapy Collaboration with Institut Pasteur Targeting Important Pediatric and Adult Deafness Segments

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Analyse van de cashflow

Ontdek gezonde bedrijven